Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
argenx SEARGX -2.62%78 Receivables Turnover is 0.87 as of Mar. 2026. GuruFocus rates ARGX with a GF Score™ of 78/100 and a GF Value™ of $1,435.94 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 841 Biotechnology companies, argenx SE ranks worse than 64.68% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. argenx SE's Revenue for the
three
months ended in Mar. 2026 was $1,298 Mil. argenx SE's average Accounts Receivable for the
three
months ended in Mar. 2026 was $1,490 Mil.
Hence, argenx SE's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.87.
argenx SE (NAS:ARGX) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
argenx SE Receivables Turnover Related Terms
argenx SE Receivables Turnover Historical Data
* Premium members only.
The historical data trend for argenx SE's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARGX vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, argenx SE's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where argenx SE's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (ARGX) has a Receivables Turnover of 0.87 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on argenx SE and its competitors. According to the industry distribution chart, argenx SE ranks #544 out of 841 companies in the Biotechnology industry, placing it in the top 64.7%.
Is argenx SE's Receivables Turnover too high?
argenx SE's current Receivables Turnover is 0.87. The Biotechnology industry median Receivables Turnover is 5.28. argenx SE's value of 0.87 is 83.5% below this industry median. Based on the distribution chart, argenx SE ranks #544 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, argenx SE has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #544 out of 841 companies for Receivables Turnover. This places argenx SE in the lower half of its industry. The industry median Receivables Turnover is 5.28. argenx SE's value of 0.87 is 83.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. argenx SE's current Receivables Turnover of 0.87 is 83.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on argenx SE and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current Receivables Turnover is 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,435.94, compared to a current price of $853.40 — trading 40.6% below its estimated fair value. The current Receivables Turnover is 0.87 and 83.5% below the Biotechnology industry median of 5.28. argenx SE's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For argenx SE (ARGX), the current Receivables Turnover is 0.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (ARGX) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of $853.40 is trading 40.6% below its estimated GF Value™ of $1,435.94.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for ARGX:
Receivables Turnover: 0.87
GF Value™: $1,435.94 vs. price of $853.40 (40.6% below fair value)
Industry Position: 83.5% below the Biotechnology median (#544 of 841)
No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score
Get the complete analysis for ARGX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARGX has been successfully added to your 
